Diabetes drugs metformin, gliclazide and repaglinide proved more effective than other treatments in lowering the risks of cardiovascular disease and death, according to a study of more than 100,000 Danish people older than 20. Glimepiride, glibenclamide, glipizide and tolbutamide were linked to a higher risk of all-cause mortality as well as to a higher risk of heart attack, stroke and cardiovascular death, the study found.

Related Summaries